Stockreport

Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monda...

Allogene Therapeutics, Inc.  (ALLO) 
Last allogene therapeutics, inc. earnings: 2/27 04:30 am Check Earnings Report
PDF SOUTH SAN FRANCISCO, Calif., April 10, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the devel [Read more]